吸入糖皮质激素联合茶碱与联合长效β2受体激动剂治疗哮喘的临床疗效对比分析
2017-10-25聂洪洲
聂洪洲
[摘要] 目的 对比哮喘患者用吸入糖皮质激素联合茶碱与联合长效β2受体激动剂治疗的临床疗效。 方法 选取2014年1月~2016年1月期间于我院收治的150例支气管哮喘患者作为研究对象,将150例患者按照治疗方法分为两组,对照组75例用糖皮质激素(布地奈德混悬液)与茶碱联合治疗,研究组75例用糖皮质激素(布地奈德混悬液)与长效β2受体激动剂(昔萘沙美特罗气雾剂)联合治疗,比较两组第一秒用力呼气容积(FEV1)和临床疗效。 结果 研究组总有效率为89.33%明显高于对照组的72.00%,差异有统计学意义(P<0.05)。治疗2周末、治疗4周末两组FEV1与治疗前比较出现明显升高,差异有统计学意义(P<0.05);治疗2周末、治疗4周末研究组FEV1明显高于对照组,差异有统计学意义(P<0.05)。 结论 吸入糖皮质激素与长效β2受体激动剂联合治疗哮喘的效果更为理想,可使患者的临床症状快速緩解,显著改善患者的FEV1水平,优势显著,可作为一种有效的治疗哮喘的方法在临床推广应用。
[关键词] 哮喘;糖皮质激素;茶碱;β2受体激动剂
[中图分类号] R562.25 [文献标识码] B [文章编号] 1673-9701(2017)23-0039-03
[Abstract] Objective To compare the efficacy of inhalation of glucocorticoid and theophylline with that of inhaled glucocorticoid and long-acting β2 agonist in the treatment of asthmatic patients. Methods A total of 150 patients with bronchial asthma admitted in our hospital from January 2014 to January 2016 were enrolled in this study. The patients were divided into two groups according to the treatment methods. 75 cases of control group were treated with glucocorticoid (budesonide suspension) and theophylline. The study group of 75 cases was treated with glucocorticoid (budesonide suspension) and long-acting β2 receptor agonist(xinaphthaotetil aerosol) combination therapy. The first-second forced expiratory volume(FEV1) and clinical efficacy between the two groups were compared. Results The total effective rate(89.33%) of the study group was significantly higher than that of the control group(72.00%), and the difference was statistically significant(P<0.05). FEV1 of the study group and the control group at the end of 2 weeks and 4 weeks after treatment were significantly higher than those before treatment, with significant difference(P<0.05). FEV1 of the study group at the end of 2 weeks and 4 weeks after treatment was significantly higher than that of the control group, and the difference was significant(P<0.05). Conclusion Inhaled glucocorticoid and long-acting β2 receptor agonist in the treatment of asthma is more effective, which can promptly relieve the clinical symptoms of patients, significantly improve the patient's FEV1 level, with significant advantages, and can be used as an effective treatment of asthma methods in clinical application.
[Key words] Asthma; Glucocorticoid; Theophylline; β2 receptor agonist
支气管哮喘简称为哮喘,是临床常见的一种疾病,以咳嗽、喘息、胸闷或胸痛等为主要临床表现,该病病程长,迁延难愈、易反复发作,是对患者生活质量造成严重影响的严重疾病之一[1]。支气管哮喘如及时给予有效方案干预或者给予规范化治疗后,不仅可缓解大部分患者的临床症状,还可改善患者的肺功能,否则患者生命安全可能会受到威胁[2]。世界卫生组织调查发现,全世界的哮喘患者数量约为1.5亿,近年来,随着空气污染现象的凸显,支气管哮喘发病率呈现不断升高的趋势,患者的发病年龄也有所提前,因此,治疗有效药物的选择是尽快缓解患者临床症状、改善肺功能的关键[3]。虽然临床多种药物均可对哮喘进行治疗,但其效果也优劣不一,本文共收集150例支气管哮喘患者作为研究对象,分别用吸入糖皮质激素联用茶碱与联用长效β2受体激动剂治疗,对比不同治疗方案的临床疗效,现报道如下。……
